RT Journal Article
SR Electronic
T1 COVID-19 in Tunisia (North Africa): IgG and IgG subclass antibody responses to SARS-CoV-2 according to disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.01.22271696
DO 10.1101/2022.03.01.22271696
A1 Benabdessalem, Chaouki
A1 Marzouki, Soumaya
A1 Hamouda, Wafa Ben
A1 Trabelsi, Khaled
A1 Boumaiza, Mohamed
A1 Hamouda, Sonia Ben
A1 Ouni, Rym
A1 Bchiri, Soumaya
A1 Chaaban, Amani
A1 Gdoura, Meriem
A1 Gorgi, Yousr
A1 Sfar, Imen
A1 Yalaoui, Sadok
A1 Khelil, Jalila Ben
A1 Hamzaoui, Agnes
A1 Abdallah, Meya
A1 Cherif, Yosra
A1 Petres, Stéphane
A1 Pun Mok, Chris Ka
A1 Escriou, Nicolas
A1 Quesney, Sébastien
A1 Dellagi, Koussay
A1 Bettaieb, Jihene
A1 Rourou, Samia
A1 Barbouche, Mohamed Ridha
A1 Ahmed, Melika Ben
YR 2022
UL http://medrxiv.org/content/early/2022/03/02/2022.03.01.22271696.abstract
AB Coronavirus disease 2019 (COVID-19) expresses a wide spectrum of disease severity. We investigated the profile of IgG and IgG subclass antibody responses to SARS– CoV-2 in Tunisian patients with COVID-19 according to disease severity (86 patients with severe disease and 63 with mild to moderate disease). Two in house developed ELISA with excellent performance were used to test for antibodies to the nucleocapsid (N) protein and the receptor-binding domain of the spike antigen (S-RBD) of SARS-CoV-2. IgG, IgG1 and IgG3 antibodies were significantly higher in patients with severe disease compared to non-severe disease. Antibodies to S-RBD or the N protein were dominated by IgG1 and IgG3 or IgG1/IgG3 and IgG2 subclasses respectively. In patients with severe disease, IgG antibodies ‘ appearance to S-RBD was delayed compared to the N protein. IgG subclass imbalance may reflect the pathophysiology of COVID-19 and may herald disease aggravation. This study brings information on the immune responses to SARS-CoV-2 in North African patients and completes the picture drawn on COVID-19 in different African populations and worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the URGENCE COVID 19 fundraising campaign of Institut Pasteur. This study was also funded by the French Ministry for Europe and Foreign Affairs (MEAE) via the project REPAIR (International Pasteurian research program in response to coronavirus in Africa) coordinated by the Pasteur International Network Association. This work received financial support by the Ministry of Higher Education and Scientific research in Tunisia (PRFCOV19 D5P1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institut Pasteur de Tunis ethical committee (2020/21/I/LR16IPT/V2).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAbbreviationsADCCAntibody-dependent cellular cytotoxicityADEAntibody-dependent enhancementAUCArea under curveCOVID-19Coronavirus disease 2019E. coli:Escherichia coliELISAEnzyme-Linked Immunosorbent AssayHRPHorseradish peroxidaseLBLuria BrothLIPSLuciferase immunoprecipitation systemMALDI-TOFMatrix assisted laser desorption ionization-time of flightNNucleocapsid proteinPBSPhosphate buffered salineROCReceiver operating curveRT-PCRReverse transcription polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome coronavirus 2S-RBDReceptor-binding domain of the spike protein